In AUD patients with diabetes who start GLP-1 receptor agonists or SGLT2 inhibitors, do you change the intensity or timing of liver fibrosis monitoring, and which on-treatment signals (labs vs elastography vs clinical events) would you rely on to adjust follow-up?

I do not alter my surveillance for progression or regression of fibrosis when AUD patients with diabetes start GLP-1 receptor agonists or SGLT2 inhibitors. I favor FibroScan liver stiffness measurement in patients who have not reached cirrhosis. The interval I favor is every 6-12 months. In patients...